Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole nuclei, and its clinicopathological significance

Jiang,Huiyong; Bai,Xiaoyan; Meng,Fanjun; Zhang,Cheng; Zhang,Xuefeng

doi:10.3892/ol.2014.2001

Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole nuclei, and its clinicopathological significance

Authors:
- Huiyong Jiang
- Xiaoyan Bai
- Fanjun Meng
- Cheng Zhang
- Xuefeng Zhang
View Affiliations

Affiliations: Department of General Surgery, General Hospital of Shenyang Military Area Command, Shenyang, Liaoning 110840, P.R. China, Division of Nephrology, Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Gastroenterology, No. 202 Hospital of People's Liberation Army, Shenyang, Liaoning 110003, P.R. China
Published online on: March 28, 2014 https://doi.org/10.3892/ol.2014.2001
Pages: 1954-1958

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human epidermal growth factor receptor 2 (HER2) amplification and overexpression are associated with poor prognosis and resistance to cytotoxic drugs in patients with breast cancer. Increases in the number of HER2 gene copies have been shown to be associated with chromosome 17 polysomy. The use of whole, intact nuclei for fluorescence in situ hybridization (FISH) assay improves the accuracy of the results. FISH analysis of whole nuclei (WNFISH) and immunohistochemistry (IHC) were used to analyze HER2 gene amplification and HER2 protein expression in 109 breast cancer specimens. Chromosome 17 polysomy and its correlations with HER2 gene amplification, HER2 protein expression and the clinicopathological outcomes of the patients were also investigated. Among the 109 cases, WNFISH detected HER2 amplification in 30 cases, equivocal amplification in 19 cases and no amplification in 60 cases. WNFISH detected chromosome 17 centromere (CEP17) polysomy in 37 cases and no polysomy in 72 cases. Among the 109 cases assessed by tissue microarray and IHC, 31 cases were HER2‑negative, 14 cases were scored 1+, 23 cases were scored 2+ and 41 cases were scored 3+. The results demonstrated that in the cases with chromosome 17 polysomy, the HER2 gene was amplified, HER2 protein expression was increased and the incidences of nuclear atypia and lymph node metastases were higher compared with those in the cases without chromosome 17 polysomy. Chromosome 17 polysomy may correlate with increased malignant potential and metastatic spread in breast cancer.

View Figures

View References

1	McPherson K, Steel CM and Dixon JM: Breast cancer-epidemiology, risk factors, and genetics. BMJ. 321:624–628. 2000. View Article : Google Scholar : PubMed/NCBI
2	Gschwind A, Fischer OM and Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 4:361–370. 2004. View Article : Google Scholar : PubMed/NCBI
3	Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 25:118–145. 2007. View Article : Google Scholar
4	Akiyama T, Sudo C, Ogawara H, et al: The product of the c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 232:1644–1646. 1986. View Article : Google Scholar : PubMed/NCBI
5	Dal Lago L, Durbecq V, Desmedt C, et al: Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther. 5:2572–2579. 2006.PubMed/NCBI
6	Ma Y, Lespagnard L, Durbecq V, et al: Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res. 11:4393–4399. 2005. View Article : Google Scholar : PubMed/NCBI
7	Reddy JC, Reimann JD, Anderson SM and Klein PM: Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 7:153–157. 2006. View Article : Google Scholar : PubMed/NCBI
8	Reinholz MM, Bruzek AK, Visscher DW, et al: Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 10:267–277. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zhang W and Yu Y: The important molecular markers on chromosome 17 and their clinical impact in breast cancer. Int J Mol Sci. 12:5672–5683. 2011. View Article : Google Scholar : PubMed/NCBI
10	Downs-Kelly E, Yoder BJ, Stoler M, et al: The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 29:1221–1227. 2005. View Article : Google Scholar
11	Bose S, Mohammed M, Shintaku P and Rao PN: Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J. 7:337–344. 2001. View Article : Google Scholar : PubMed/NCBI
12	Farabegoli F, Ceccarelli C, Santini D, et al: c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples. Int J Cancer. 84:273–277. 1999. View Article : Google Scholar : PubMed/NCBI
13	Pritchard KI, Munro A, O’Malley FP, et al: Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Res Treat. 131:541–551. 2012. View Article : Google Scholar : PubMed/NCBI
14	Lal P, Salazar PA, Ladanyi M and Chen B: Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn. 5:155–159. 2003. View Article : Google Scholar : PubMed/NCBI
15	Varshney D, Zhou YY, Geller SA and Alsabeh R: Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 121:70–77. 2004. View Article : Google Scholar : PubMed/NCBI
16	Rosenberg CL: Polysomy 17 and HER-2 amplification: true, true, and unrelated. J Clin Oncol. 26:4856–4858. 2008. View Article : Google Scholar : PubMed/NCBI
17	Vanden Bempt I, Van Loo P, Drijkoningen M, et al: Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 26:4869–4874. 2008.PubMed/NCBI
18	Jiang HY, Zhang SQ and Zhao T: A new method to make nuclei or cell microarrays. Diagn Mol Pathol. 15:109–114. 2006. View Article : Google Scholar : PubMed/NCBI
19	Tse CH, Hwang HC, Goldstein LC, et al: Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol. 29:4168–4174. 2011. View Article : Google Scholar : PubMed/NCBI
20	Li X, Wan L, Shen H, et al: Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis. J Thorac Oncol. 7:76–84. 2012. View Article : Google Scholar : PubMed/NCBI
21	Birner P, Oberhuber G, Stani J, et al: Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 7:1669–1675. 2001.PubMed/NCBI
22	Watters AD, Going JJ, Cooke TG and Bartlett JM: Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 77:109–114. 2003. View Article : Google Scholar : PubMed/NCBI
23	Risio M, Casorzo L, Redana S and Montemurro F: HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. Oncol Rep. 13:305–309. 2005.PubMed/NCBI
24	Hammock L, Lewis M, Phillips C and Cohen C: Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol. 34:1043–1047. 2003.
25	Pritchard KI, Shepherd LE, O’Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 354:2103–2111. 2006. View Article : Google Scholar : PubMed/NCBI
26	Ejlertsen B, Jensen MB, Nielsen KV, et al: HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol. 28:984–990. 2010. View Article : Google Scholar : PubMed/NCBI